AbbVie’s stock climbs 40% over the past year but trades at 18x forward earnings, below the S&P 500’s 21x multiple.
AbbVie (NYSE: ABBV) hit a new 52-week high Monday, rising nearly 40% over the past 12 months. The healthcare giant’s year-to-date gain of 11% outpaces the S&P 500’s 8% advance but lags broader growth stock rallies.
Despite its recent climb, ABBV trades at less than 18 times estimated future earnings, below the S&P 500’s 21x average. Analysts suggest the stock’s valuation reflects lingering concerns over healthcare policy but remains supported by consistent earnings performance.
The stock’s resilience has reinforced its status as a blue-chip holding, though investors debate whether its valuation has become overextended after the rally.